amobarbital

Clinical trial activity

1 trials · 2 clinical orgs · 0 marketing orgs

Earliest trial started Aug 31, 2021 (NCT04589611)

Indications

Mechanism of action

• Unspecified targetOTHER

  Unknown

  The mechanisms by which sodium amobarbital reduces both pain and sensory abnormalities are unknown. Possibly more than one mechanisms account for the observed effects. Sodium amobarbital has been shown to produce a reversible depression of the central nervous system (CNS), may exert a euphoric effect, and preferentially suppresses polysynaptic responses both at the level of the spinal cord and subcortical and cortical levels. On the peripheral nervous system, sodium amobarbital selectively depresses transmission through autonomic ganglia and reduction of choline esters nicotinic excitation. The inhibitory effects of sodium amobarbital have been reported to occur at the gamma-aminobutyric acid (GABA) sites, and at the NMDA (n-methyl d-aspartate) receptor as a non-competitive receptor antagonist. In general, sodium amobarbital enhances GABA-A inhibition in multiple peripheral and central nervous system sites and also exerts noncompetitive antagonistic effects on AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors, as well as kainate and NMDA receptors. It is possible that the noncompetitive NMDAreceptor antagonistic action of sodium amobarbital may be responsible for the substantial alteration of cutaneous (centrally mediated) hyperesthesia. (PMID: 19264049 )